anti-EMMPRIN monoclonal antibody

Anti-EMMPRIN monoclonal antibodies are a class of biologic therapies designed to target EMMPRIN (Extracellular Matrix Metalloprotease Inducer), also known as CD147. EMMPRIN is a transmembrane glycoprotein frequently overexpressed in various malignancies, where it plays a critical role in promoting tumor progression, angiogenesis, and epithelial-to-mesenchymal transition (EMT) by inducing the production of matrix metalloproteinases (MMPs). Several experimental antibodies have been developed, including CNTO3899 (a chimeric blocking antibody) and hMR18-mAb. These agents have been investigated in preclinical and early clinical research for indications such as head and neck squamous cell carcinoma (HNSCC), pancreatic cancer, and breast carcinoma, often demonstrating the ability to arrest tumor growth and reduce cell proliferation.

Other names

anti-CD147 monoclonal antibodyanti-CD-147 monoclonal antibodyanti-CD 147 monoclonal antibodyanti-extracellular matrix metalloproteinase inducer monoclonal antibody